ATRIUM acted as exclusive financial advisor to Royal DSM in the acquisition of Glycom A/S.
Glycom is the world’s leading supplier in the Human Milk Oligosaccharides (HMO) market. HMOs are complex carbohydrates that exist naturally in large quantities in mother’s milk. HMOs are used globally as a key ingredient in infant nutrition, children and adult supplements and foods. Glycom has made the scientific breakthroughs necessary to produce HMOs and make them commercially available for the first time. Glycom is the only fully integrated HMO player with its own product development, preclinical and clinical development, regulatory and large-scale production.
DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.
Glycom will become part of DSM’s Human Nutrition & Health division. The acquisition of Glycom is part of a larger, targeted strategy for DSM to develop its position within HMOs.
For more information, please visit: ATRIUM Partners
